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Summary
The use of inhaled therapies for chronic respiratory infections in cystic ﬁbrosis represents a
substantive treatment burden to patients. In this paper, we review the evidence supporting
two commonly used inhaled antibiotic regimens for chronic respiratory infections –
continuous vs. intermittent (28 days on followed by 28 days off) therapy. We included
trials of good methodological quality and excluded those in which the primary intent was
eradication. In total, we included 13 trials (5 of intermittent therapy and 8 of continuous
therapy) and summarized their main ﬁndings, placing particular emphasis on change in
FEV1, emergence of resistance and patient adherence. What is evident from our review is
that both continuous and intermittent inhaled therapies work. Although an intermittent
regimen would be intuitively “better” in terms of cost savings and patient tolerability,
there is currently a lack of head-to-head trials that compare the same drugs (and dosages)
using the two different regimens to make such a recommendation based on robust clinical
evidence.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
The earliest known description of cystic ﬁbrosis (CF) was in
1938 by Dorothy Andersen of the New York Babies Hospital.1
Since that time, survival from the disease has increased
steadily. Only 3% of adults with CF born between 1947
and 1949 could expect to survive to 30 years of age.2 The
median predicted survival from the 2009 UK registry is now
34 years,3 and the previously predicted survival to >50 years
of age for children born in 2000 is now looking realistic, even
in the absence of effective therapy to correct the genetic
defect.4
During the 1970s and 1980s, the main emphasis on CF
treatment focused on antibiotics. Although intravenous (IV)
access techniques improved and patients lived longer, many
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became chronically infected with Pseudomonas aeruginosa.
In the UK, 36% of the CF population is chronically infected
with P. aeruginosa and 15% with Staphylococcus aureus.3 In
the US, the ﬁgures are 52% and 51%, respectively.5
Reduced levels of chronic P. aeruginosa infection have
been attributed by some to the aggressive use of nebulized
antibiotics, regular microbiological monitoring, prompt
antibiotic treatment of ﬁrst isolates, and intensive use of
IV antibiotics when inhaled antibiotics have failed.6–8 One
Belgian center achieved a rate of chronic P. aeruginosa
of 20.7%, compared with a national average of 48%.6 In
the UK, Lee and colleagues reported a decline in the
number of patients with chronic P. aeruginosa infection,
from 24.5% to 18.1% (P < 0.05), which was thought to be
the result of these measures.7 An increase in representation
among individuals with a relatively “mild” CF phenotype
identiﬁed by molecular diagnostic techniques may also have
contributed to the observed decrease in prevalence of
chronic P. aeruginosa infection in the population.
0954-6111$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
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Continuous vs intermittent therapy: how did
we get here?
Three antibiotics are commonly used for inhalation therapy
in patients with CF: tobramycin, colistin, and aztreonam.
Colistin has been in use in Europe since the 1980s, following
studies by Littlewood and colleagues9 and Jensen and
associates.10 Its use remains widespread, due largely to its
tolerability proﬁle and the fact that P. aeruginosa resistance
is relatively rare.11 Inhaled tobramycin has been the
preferred chronic suppressive therapy against P. aeruginosa
in North America since the landmark trial by Ramsey and
collaborators in 1999.12 Only one head-to-head comparison
of inhaled colistin vs. tobramycin has been conducted to
date,13 and although tobramycin appeared to be more
efﬁcacious, the dose of colistin used was 1MU twice daily,
which is only half the maximum recommended dose. Inhaled
aztreonam is relatively new to the market, having been
granted US Food and Drug Administration (FDA) approval for
use in 2010.
The speciﬁc reasons for choice of inhaled antibiotic are
beyond the scope of this article. A critical question in the
selection of a therapeutic regimen of chronic suppressive
aerosolised antibiotics for CF is whether to use continuous
or intermittent therapy (usually 28-day on/off cycles). If
the efﬁcacy and safety of the two approaches were similar,
then intermittent therapy would win hands down because
of increased convenience and reduced cost. Two other
potential advantages, although intuitively sensible, should
be accepted only if robust evidence is present – namely,
greater adherence to treatment and reduced antimicrobial
resistance. Comparison of the two approaches to scheduling
is difﬁcult, because historically, a continuous regimen has
been used with aerosolised colistin and an intermittent
regimen with tobramycin (and lately with aztreonam).
The origin of the 28-day intermittent treatment cycle
can be traced back to a trial of 3-times-daily nebulized
tobramycin, administered continuously for 3 months. This
study was conducted in 22 patients (no control group)
in the 1980s.14 Mean forced expiratory volume in 1
second (FEV1) improved signiﬁcantly in these patients
at 28 days, but the improvement had diminished by
the end of 3 months of treatment and was close to
baseline approximately 1 month after treatment ceased. In
addition, substantially more bacterial isolates with reduced
susceptibility to tobramycin were observed after 3 months
of nebulized tobramycin, although this proportion declined
over the following year (off treatment). A subsequent
randomized, blinded, placebo-controlled, crossover study
by Ramsey and colleagues15 (Table 1) again reported
signiﬁcant improvements in FEV1 and forced expiratory ﬂow
between 25% and 75% of forced vital capacity (FEF25%–75%)
during 28 days of treatment with inhaled tobramycin –
improvements that diminished from days 28 to 56 of
treatment. There was also an associated decrease in
P. aeruginosa sputum density by a factor of 100 with
tobramycin treatment during the ﬁrst 28 days, but less of
a decline following the ﬁrst 28 days.15 Based on these two
studies, it was postulated that continued administration of
tobramycin beyond 28 days would not result in an increased
treatment effect and was more likely to lead to selection
for bacterial isolates resistant to tobramycin.14
Intermittent therapy has been accepted as “standard of
care” by such regulatory agencies as the FDA. It is likely that
pharmaceutical companies undertaking clinical trials of new
formulations of inhaled antibiotics will be expected to com-
pare their product with intermittent nebulized tobramycin
and presumably will adopt an intermittent regimen for the
new product, as well for current ongoing trials.
Comparisons of continuous vs. intermittent
therapy
Only one trial (Nikolaizik et al., 200821) compared
continuous vs. intermittent therapy. Different doses of
tobramycin were used in the two treatment arms, rendering
comparison difﬁcult. No other head-to-head comparisons of
the same dose of inhaled antibiotic administered either
continuously or in 28-day on/off cycles have been conducted
to date, thus a direct comparison of safety and efﬁcacy (or
adherence and antimicrobial resistance) is not possible.
So can we make indirect comparisons? The randomized,
controlled trials (RCTs) that have evaluated long-term
aerosolised antibiotic therapy in patients with CF have been
compared in an exhaustive systematic review, conducted
by Ryan and coworkers.22 These 19 trials (with 1724
participants) found that lung function (as measured by FEV1)
improved and exacerbations of respiratory symptoms were
less frequent in the antibiotic-treated group vs. the placebo-
treated group.
In this article, we have categorized the RCTs of nebulized
antibiotics for chronic suppressive therapy in CF conducted
to date according to whether the regimen was intermittent
(Table 1) or continuous (Table 2). Table 3 lists trials in which
treatment was administered for 28 days only, which cannot
be said to be intermittent or continuous, and have been
included for comparison. As in the systematic review, RCTs of
poor methodological quality or <4 weeks’ duration have been
omitted and six new studies have been added.13,18,19,30–32 We
have omitted trials in which the intention of therapy was
eradication of P. aeruginosa (not trials of chronic therapy).
Of note, the study of intermittent aztreonam lysine by
Oermann and colleagues18 is a continuation trial of two
previous trials: AIR-CF119 and AIR-CF2,20 respectively. The
Nikolaizik trial21 is not included in any of the tables, as
it compares continuous and intermittent regimens, and a
trial that considered only patients with Burkholderia cepacia
complex has been omitted as well.34
Trials of intermittent therapy
Table 1 illustrates trials of intermittent therapy. These
5 trials have enrolled 1293 participants, with a median
treatment duration of 20 weeks (range, 12 to 72 weeks).
Whenever FEV1 was a recorded outcome (not always the
primary outcome), these data have been included in the
table. Although FEV1 is not necessarily the most clinically
relevant outcome (or the most important to patients), it
is objective, has been reported most consistently, and is
closely related to prognosis.35 Hence, it is included as the
outcome measure in Table 1, in order to allow comparison
between trials. In 3 of the 5 trials, the FEV1 improved to a
signiﬁcantly greater degree in the active vs. the comparator
group. Of the remaining 2 trials, Oermann and associates18
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did not report a statistical test, although the authors did
comment that generally there was greater improvement
in FEV1 observed in the 3-times-daily compared with the
twice-daily treatment group. The remaining study by Murphy
and coworkers16 was terminated early and did not detect
a signiﬁcant improvement in FEV1, although the trend
appeared to favor active treatment.
Recent trials have used a primary outcome measure that
is more relevant to patients. McCoy and coworkers20 used
time to IV antipseudomonal antibiotic use (21 days longer in
the group receiving nebulized aztreonam lysine; P = 0.007).
The primary efﬁcacy endpoint in the study by Retsch-Bogart
and colleagues19 was change in patient-reported respiratory
symptoms on the Respiratory Scale of the CF Questionnaire-
Revised36 (9.7-point improvement; P = 0.001; a minimum
difference of 5 points was set a priori).
Few side effects have been reported in these trials,
although tinnitus (a recognized adverse effect associated
with tobramycin use) occurred more often in the active
group in the largest trial of inhaled tobramycin.12 Clearly,
nebulized antibiotics have the potential to do harm. Along
with tinnitus, acute kidney injury has been reported with
the use of nebulized tobramycin,37 although the occurrence
is rare. The use of 28-day on/off cycles will reduce lifetime
drug exposure, and, hence, the risk for renal toxicity and
ototoxicity with nebulized tobramycin use. Furthermore, in
animal models, the half-life of aminoglycoside antibiotics in
the hair cells of the inner ear is measured in months,38 so an
alternate monthly regimen should allow for improved drug
clearance.
So what about antimicrobial resistance? Burns and
associates39 reported the antimicrobial resistance data
from the pivotal trial of nebulized tobramycin,12 using
the accepted minimum inhibitory concentration (MIC)
breakpoints for parenteral therapy. The percentage of
patients with a strain of P. aeruginosa having an MIC above
the parenteral breakpoint (>16mg/mL) increased from 13%
to 23% among individuals receiving inhaled tobramycin over
the 24-week trial (vs. a decrease from 10% to 8% among
controls). The parenteral MIC breakpoint used to deﬁne
resistance may not be relevant in these circumstances,
however, as much higher concentrations of antibiotics are
achieved by the inhaled route. Hodson and collaborators13
reported “a small increase” in MIC following 28 days of
treatment in tobramycin-treated patients but not in colistin-
treated patients, but they presented no data. The study
of long-term nebulized aztreonam lysine18 reported no
increase in antimicrobial resistance in either arm, although
3 patients in the times-daily group experienced ﬁrst isolation
of B. cepacia after commencing the study therapy. Neither
the Burns paper39 nor the 28-day duration aztreonam lysine
trials19,20 demonstrated an increase in such other pathogens
as B. cepacia complex, Stenotrophomonas maltophilia, and
Achromobacter xylosoxidans.
Adherence to (or compliance with) treatment is usually
better in clinical trials than in routine practice. Briesacher
and colleagues40 identiﬁed 804 patients with CF and
determined their adherence to treatment by means of
claims made through occupational health insurance plans.
The authors concluded that only 7% of patients received 4
cycles of inhaled tobramycin per year (“high adherence”),
compared with the 6 cycles prescribed. High adherence
was associated with a reduced risk for hospitalization
(odds ratio, 0.4; 95% conﬁdence interval, 0.19 to 0.84)
compared with low adherence (2 cycles per year).
This is very different from the adherence reported in
clinical trials. In the studies shown in Table 1, in which
adherence has been deﬁned, the deﬁnition of satisfactory
adherence varies from participants taking 66%20 to 80%13
of prescribed doses. With both deﬁnitions, adherence was
>90%. A Canadian study estimated that about half of the
cost of nebulized tobramycin might be recouped because
of a reduced requirement for hospital-based and home IV
antibiotic treatment.41 However, poor adherence in routine
clinical practice may diminish considerably the economic
beneﬁts claimed. In addition, the demand on time is
substantial when patients are receiving inhaled antibiotics.
Administration time with nebulized tobramycin solution is
15 to 20 minutes, excluding the time required for cleaning
and sterilization of the delivery device42; this equates to
approximately 14 to 18 hours per month. An on/off regimen
would save a considerable amount of time every other
month; however, whether this would result in improved
adherence is not known.
Trials of continuous therapy
In contrast to trials of intermittent therapy, trials of
continuous nebulized antibiotics enrolled fewer participants
(206 in total; see Table 2). Where FEV1 was measured, most
patients showed an improvement, with the exception of the
study by Nolan and associates,24 in which a slightly larger
decrease in FEV1 % predicted was reported in the active
treatment group. However, the authors noted that this did
not reach statistical signiﬁcance.
Although they enrolled fewer participants, these studies
were of longer duration (median, 9 months; range, 3 to
33 months) and provided a total of 283 person-years of drug
exposure to yield data on adverse effects. The more recent
studies of intermittent therapy, however, may include open-
label continuation phases to assess long-term safety. Studies
of continuous therapy are generally older (1981 to 1989
vs. 1993 to 2010 for studies of intermittent aerosolized
antibiotic therapy). Trials in the 1980s were not subject to
the same rigorous regulations on reporting adverse events
that have applied over the last 2 decades. Nevertheless,
in trials of continuous therapy, adverse effects were no
more common in the active treatment group than in the
comparator group.
In terms of antibiotic resistance, 2 studies did not
report on this,26,28 whereas 4 reported no signiﬁcant
difference.10,23–25 Of the remaining 2 trials, MacLusky and
colleagues29 reported the development of tobramycin-
resistant P. aeruginosa in 4 of the 12 active treatment arm
patients who were originally infected with sensitive strains,
and Stead and coworkers27 reported the development of
P. aeruginosa with partial resistance in 3 patients (1 to
ceftazidime and 2 to carbenicillin), who regained full
sensitivity 1 to 2 months following completion of the trial.
Although it may well be that continuous use of some
classes of inhaled antibiotics can result in persons with
CF becoming refractory to their beneﬁcial effects, in vitro
antibiotic susceptibility testing is a notoriously poor method
for predicting the efﬁcacy of antibiotics delivered by any
route in patients with CF.43–45 For this reason, use of in
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Table 4
Current studies
Agent Company Dose Comparator Regimen ClinicalTrials.gov
identiﬁer
Aztreonam (AZLI) Gilead 75mg 3 times daily Tobramycin 300mg
twice daily
3 cycles of 28 days on/off NCT00757237
Oral ciproﬂoxacin plus
inhaled colistin
Universitaire
Ziekenhuizen,
Leuven, Belgium
30mg/kg/day
2 MU twice daily
(continuous for
3 months)
Tobramycin 300mg
twice daily for
28 days
Eradication regimens NCT01400750
Liposomal amikacin
(Arikace®)
Insmed 560mg once daily Tobramycin 300mg
twice daily
3 cycles of 28 days on/off NCT01315678
Levoﬂoxacin (MP-376) Mpex
Pharmaceuticals
240mg twice daily Tobramycin 300mg
twice daily
3 cycles of 28 days on/off NCT01270347
Levoﬂoxacin (MP-376) Mpex
Pharmaceuticals
240mg twice daily Placebo 28 days on followed by
28 days off
NCT01180634
vitro antibiotic susceptibility tests to predict the relative
long-term efﬁcacy of continuous vs. intermittent inhaled
antibiotic therapy is problematic.
Single-agent therapy vs rotation of antibiotics
We identiﬁed no clinical trials that directly compared a
single inhaled antibiotic vs the rotation of antibiotics in
patients with CF.
The way forward
From a thorough review of the literature, it is apparent that
both intermittent and continuous regimens of aerosolised
antibiotics are effective in maintaining lung function and are
associated with few adverse effects. Recent studies have
shown that aerosolised antibiotics may reduce respiratory
symptoms and defer the need for IV antibiotics. A 28-day
on/off regimen of nebulized tobramycin is associated with
an increase in antimicrobial resistance, but in general,
emergence of other pathogens is not seen with either
intermittent or continuous therapy. A major confounding
factor is the fact that trials of continuous therapy
were conducted almost a decade earlier than trials of
intermittent therapy. These trials used different antibiotics
(gentamicin and beta-lactams, as well as tobramycin) and
enrolled far smaller numbers of participants.
There are planned and ongoing studies (Table 4) of other
antibiotics, but these generally follow the precedent of
intermittent therapy. Clearly what is needed are well-
designed and adequately powered RCTs of intermittent
vs continuous therapy, using the same dose of the same
antibiotic in each arm. The challenges and limitations
associated with the designs of such trials are addressed in
the article by VanDevanter et al. in this supplement.46
Conclusion
Both intermittent and continuous inhaled antibiotics work,
although direct comparisons of their efﬁcacy are difﬁcult.
The administration of intermittent antibiotics is less time-
consuming to patients; however, whether this necessarily
means improved adherence is not yet known. It would
be easy to assume that adherence would be better with
intermittent regimens, although the opposite may also
be true if patients do not experience any appreciable
deterioration in health during “off” months and therefore
feel reluctant to resume treatment at the start of “on”
months. The cost of intermittent therapy might be less
expensive than that of continuous therapy, although this
would be true only when the same drugs (in the same
dosage) are compared head to head with both regimens,
and we have not identiﬁed any trials in which this has been
performed. Some evidence suggests that long-term use of
inhaled tobramycin is associated with increased resistance;
however, given that deterioration in lung function is the
main predictor of mortality among individuals with CF, this
factor must be taken in the context of the patient’s well-
being as a whole. In conclusion, additional trials are required
before we can base our treatment decisions, at least in
terms of scheduling strategy, on good evidence.
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